ARS Pharmaceuticals, Inc. Net Income Loss

Quick Answer

ARS Pharmaceuticals, Inc. reported Net Income Loss of -$171.30 million for the year ending 2025.

  • ARS Pharmaceuticals, Inc. showed a decrease of -2,241.8% in Net Income Loss from 2024 to 2025.
  • This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), ARS Pharmaceuticals, Inc.'s Net Income Loss has declined by 419.9%.
  • Historical annual values: Fiscal year 2025: -$171.30 million | Fiscal year 2024: $8.00 million | Fiscal year 2023: -$54.37 million | Fiscal year 2022: -$34.68 million | Fiscal year 2021: -$20.24 million | Fiscal year 2020: -$32.95 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: